Kings Technology Evaluation Centre (KiTEC) published in Applied Health Economics and Health Policy a study as part of a NICE Medical Technology Guidance. The study investigated the use of Virtual Touch Quantification (VTq) to diagnose and monitor liver fibrosis in Hepatitis B and C.
In September 2015, NICE issued final guidance (MTG27) on this technology specifically in relation to liver fibrosis in patients with chronic hepatitis B or hepatitis C, and this study summarised this guidance and the evaluation process.
The study listed the following key points for decision makers:
- Virtual Touch™ Quantification (VTq) is a software application used with Siemens Acuson ultrasound scanners to assess the stiffness of liver tissue and the stage of liver fibrosis.
- The National Institute for Health and Care Excellence Medical Technology Evaluation Programme assessed the VTq software for use in people with hepatitis B or C and the External Assessment Centre estimated cost savings per patient for the VTq software in hepatitis patients was £53 when compared to transient elastography and £434 when compared to liver biopsy.
- In September 2015, the VTq software was recommended for adoption within the National Health Service (NHS) for patients with hepatitis B or C for diagnosis and monitoring of liver fibrosis.